Review reveals how epigenetic and post-translational modifications regulate endothelial-mesenchymal transition, highlighting therapeutic targets for fibrosis and cardiovascular disease.
Endothelial-mesenchymal transition (EndMT) is a biological process in which endothelial cells lose intercellular junctions and endothelial characteristics under specific pathophysiological stimuli and acquire mesenchymal traits. It plays a critical role in cardiac development, tissue fibrosis, tumor metastasis, atherosclerosis, and other diseases. In recent years, growing evidence has demonstrated that epigenetic modifications and post-translational modifications are central to the precise regulation of EndMT initiation and progression. This review systematically elaborates on how epigenetic mechanisms-such as DNA methylation, histone modifications, and non-coding RNAs-as well as post-translational modifications, including protein phosphorylation, acetylation, and ubiquitination, regulate EndMT by modulating key signaling pathways (e.g., TGF-β, Wnt, Notch) and transcription factors (e.g., Snail, Slug, Twist, ZEB1/2). A deeper understanding of these regulatory networks may provide novel diagnostic biomarkers and therapeutic strategies for diseases targeting EndMT.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: